Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week , Says NanoViricides

• The FDA approved insulin efsitora alfa-gobe, marketed as Onswik, during the week of September 20. • Other regulatory actions included a priority review for Insmed's Arikayce for MAC lung disease and a label update for Winrevair to include phase 3 HYPERION trial data for adults with pulmonary arterial hypertension.

• NanoViricides began enrolling and dosing patients for a clinical trial of the oral drug NV-387 to treat Ebola on or about September 23rd. • The trial targets the Bundibugyo Ebolavirus variant, for which there is currently no approved treatment or vaccine.

• The U.S. Food and Drug Administration approved the humanized monoclonal antibody palivizumab in 1998 to prevent respiratory syncytial virus (RSV) in high-risk infants. • Clinical trials showed the treatment reduced RSV-related hospitalizations from 10.6% in the placebo group to 4.8% in treated infants.

• NanoViricides, Inc. has begun enrolling patients in the Democratic Republic of the Congo for a Phase II clinical trial of its NV-387 oral gummies to treat Ebolavirus. • The trial focuses on establishing a safe dosing protocol and evaluating the efficacy of the gummies against the Ebola virus infection.

• The CDC is monitoring ongoing outbreaks of clade I and clade II monkeypox across the United States. • Fall 2025 recorded the highest monthly case counts since the initial peak of the outbreak in 2022.

• Pfizer will present 45 cancer research abstracts at the ESMO congress from October 23-27. • The data covers breast, genitourinary, and lung cancers, featuring investigational candidates atirmociclib and tivunatamig.

• The global liquid biopsy market is projected to grow at a compound annual growth rate of approximately 12% over the next five years. • This expansion is driven by a rising global burden of cancer and an increased demand for rapid, early disease detection.

• A panel of 30 journalists, physicians, and health researchers from the Foundation for Informed Medical Decision Making reviewed the online health coverage of major news organizations. • The project focused specifically on stories making claims about the safety or efficacy of medical treatments to determine which sites provide the most reliable information.

• Invivyd began dosing the first participants in the LIBERTY phase 3 trial for its VYD2311 COVID-19 candidate. • The study compares VYD2311 against an mRNA vaccine and the combined coadministration of both treatments.

• The Centers for Medicare & Medicaid Services (CMS) is taking actions to eliminate fraud in the healthcare system by canceling unauthorized enrollments in the Federal Health Insurance Marketplace. • Approximately 315,000 unauthorized enrollments covering over 760,000 individuals have been canceled, which is expected to result in a return of roughly $2.2 billion in taxpayer-funded subsidies.

• GlobalRPh publishes a weekly medical news roundup, reviewing developments from the FDA, CDC, WHO, NIH, and major medical journals for the week of September 11-17, 2026. • The roundup covers clinically important developments from these sources, aiming to inform healthcare professionals about changes that may affect clinical practice, medication management, and public health response.